Ataraxis Breast RISK

JSON twin: https://www.healthaidb.com/software/ataraxis-breast-risk.json

Company Name

Ataraxis

Product URL

https://www.ataraxis.ai/ataraxis-breast

Company URL

https://www.ataraxis.ai/

Categories

• clinical Care
• diagnostic Support
• predictive Analytics
• oncology Care
• laboratory Testing
• Clinical
• Diagnostic
• Oncology
• Laboratory Services

Summary

Ataraxis Breast RISK is an AI-driven prognostic platform that analyzes pathology slides to predict breast cancer recurrence and mortality, aiding personalized treatment decisions across all breast cancer subtypes.

Description

Ataraxis Breast RISK utilizes multi-modal patient data, including H&E-stained pathology slides from biopsies and surgical specimens, to generate personalized risk profiles for invasive breast cancer patients. It has been clinically validated to be over 50% more accurate than standard 21-gene assays, providing independent prognostic information alongside clinical and genomic data. The platform delivers results within one business day and requires no additional tissue processing, working with both core needle biopsy and surgical resection samples. It is available through a CLIA-certified laboratory in Orlando, FL, and is intended to assist physicians in assessing the risk of breast cancer recurrence, death, and therapeutic benefit for patients diagnosed with invasive breast cancer.

Api Available

unknown

Certifications

• FDA 510(k) exempt
• CE/MDR
• ONC
• ISO 27001

Company Founding

2022

Company Offices

• United States

Compliance

• HIPAA
• CLIA '88

Customers

• Ataraxis Breast RISK is intended to help physicians assess the risk of breast cancer recurrence, death, and therapeutic benefit for patients diagnosed with invasive breast cancer.

Data Residency

US-only

Data Standards

• HL7
• DICOM

Deployment Model

• SaaS

Features

• AI-native prognostic/predictive platform for invasive breast cancer
• Utilizes multi-modal patient data, including pathology slides from standard biopsy and surgery specimens
• Predicts patient outcomes to personalize treatment decisions across all breast cancer subtypes
• Developed and validated in early-stage invasive breast cancer patients, including HR+ HER2-, TNBC, HER2+, premenopausal, and node-positive groups
• Over 50% more accurate than standard-of-care 21-gene assay
• Provides independent prognostic information to both clinical and genomic data
• Delivers results within one business day from receiving pathology slides
• Requires only H&E-stained slides; no additional histology work needed
• Compatible with core needle biopsy and surgical resection samples
• Developed and validated using data from 8,161 breast cancer patients across 15 institutions in 7 countries
• Consistently prognostic across various age, race, molecular and histological subtypes, and nodal status

Id

SW0928

Integration Partners

• QGenda
• Waystar
• Personify Health
• Definitive Healthcare
• Oracle Enterprise Healthcare Analytics
• Cerner CareTracker
• Atlas
• HealthStream Checklist

Integrations

• EHR Integration

Languages Supported

• English

Last Updated

2025-10-11

License

Commercial

Market Segment

• Enterprise
• SMB

Optional Modules

Os Platforms

• Web

Pricing Details

Contact vendor for pricing information.

Pricing Model

Subscription

Privacy Features

• BAA available
• Consent management
• Anonymization
• Data minimization

Product Code

SW0928

Product Name

Ataraxis Breast RISK

Ratings

Regions Available

• United States

Related Urls

• https://elion.health/products/ataraxis

Release Year

2025

Security Features

• Encryption
• RBAC
• SSO/SAML
• Audit logs
• 2FA

Specialties

• Breast Cancer
• Oncology
• Pathology

Support Channels

• email
• phone
• chat
• ticketing
• community
• 24x7

System Requirements

Target Users

• Clinicians
• Oncologists
• Pathologists
• Medical Researchers

Training Options

• documentation
• webinars
• live_online
• onsite
• certification

Type

product

User Reviews

Version

1.0

Alternatives

See related products

Canonical JSON

{
  "product_name": "Ataraxis Breast RISK",
  "company_name": "Ataraxis",
  "product_url": "https://www.ataraxis.ai/ataraxis-breast",
  "company_url": "https://www.ataraxis.ai/",
  "related_urls": [
    "https://elion.health/products/ataraxis"
  ],
  "product_code": "SW0928",
  "summary": "Ataraxis Breast RISK is an AI-driven prognostic platform that analyzes pathology slides to predict breast cancer recurrence and mortality, aiding personalized treatment decisions across all breast cancer subtypes.",
  "description": "Ataraxis Breast RISK utilizes multi-modal patient data, including H&E-stained pathology slides from biopsies and surgical specimens, to generate personalized risk profiles for invasive breast cancer patients. It has been clinically validated to be over 50% more accurate than standard 21-gene assays, providing independent prognostic information alongside clinical and genomic data. The platform delivers results within one business day and requires no additional tissue processing, working with both core needle biopsy and surgical resection samples. It is available through a CLIA-certified laboratory in Orlando, FL, and is intended to assist physicians in assessing the risk of breast cancer recurrence, death, and therapeutic benefit for patients diagnosed with invasive breast cancer.",
  "categories": [
    "clinical Care",
    "diagnostic Support",
    "predictive Analytics",
    "oncology Care",
    "laboratory Testing",
    "Clinical",
    "Diagnostic",
    "Predictive Analytics",
    "Oncology",
    "Laboratory Services"
  ],
  "market_segment": [
    "Enterprise",
    "SMB"
  ],
  "target_users": [
    "Clinicians",
    "Oncologists",
    "Pathologists",
    "Medical Researchers"
  ],
  "specialties": [
    "Breast Cancer",
    "Oncology",
    "Pathology"
  ],
  "regions_available": [
    "United States"
  ],
  "languages_supported": [
    "English"
  ],
  "pricing_model": "Subscription",
  "pricing_details": "Contact vendor for pricing information.",
  "license": "Commercial",
  "company_offices": [
    "United States"
  ],
  "company_founding": "2022",
  "deployment_model": [
    "SaaS"
  ],
  "os_platforms": [
    "Web"
  ],
  "features": [
    "AI-native prognostic/predictive platform for invasive breast cancer",
    "Utilizes multi-modal patient data, including pathology slides from standard biopsy and surgery specimens",
    "Predicts patient outcomes to personalize treatment decisions across all breast cancer subtypes",
    "Developed and validated in early-stage invasive breast cancer patients, including HR+ HER2-, TNBC, HER2+, premenopausal, and node-positive groups",
    "Over 50% more accurate than standard-of-care 21-gene assay",
    "Provides independent prognostic information to both clinical and genomic data",
    "Delivers results within one business day from receiving pathology slides",
    "Requires only H&E-stained slides; no additional histology work needed",
    "Compatible with core needle biopsy and surgical resection samples",
    "Developed and validated using data from 8,161 breast cancer patients across 15 institutions in 7 countries",
    "Consistently prognostic across various age, race, molecular and histological subtypes, and nodal status"
  ],
  "optional_modules": [],
  "integrations": [
    "EHR Integration"
  ],
  "data_standards": [
    "HL7",
    "DICOM"
  ],
  "api_available": "unknown",
  "system_requirements": "",
  "compliance": [
    "HIPAA",
    "CLIA '88"
  ],
  "certifications": [
    "FDA 510(k) exempt",
    "CE/MDR",
    "ONC",
    "ISO 27001"
  ],
  "security_features": [
    "Encryption",
    "RBAC",
    "SSO/SAML",
    "Audit logs",
    "2FA"
  ],
  "privacy_features": [
    "BAA available",
    "Consent management",
    "Anonymization",
    "Data minimization"
  ],
  "data_residency": "US-only",
  "customers": [
    "Ataraxis Breast RISK is intended to help physicians assess the risk of breast cancer recurrence, death, and therapeutic benefit for patients diagnosed with invasive breast cancer."
  ],
  "user_reviews": [],
  "ratings": [],
  "support_channels": [
    "email",
    "phone",
    "chat",
    "ticketing",
    "community",
    "24x7"
  ],
  "training_options": [
    "documentation",
    "webinars",
    "live_online",
    "onsite",
    "certification"
  ],
  "release_year": "2025",
  "integration_partners": [
    "QGenda",
    "Waystar",
    "Personify Health",
    "Definitive Healthcare",
    "Oracle Enterprise Healthcare Analytics",
    "Cerner CareTracker",
    "Atlas",
    "HealthStream Checklist"
  ],
  "id": "SW0928",
  "slug": "ataraxis-breast-risk",
  "type": "product",
  "version": "1.0",
  "last_updated": "2025-10-11",
  "links_json": {
    "self": "https://www.healthaidb.com/software/ataraxis-breast-risk.json"
  }
}